Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

Editas Medicine, Inc. announced that the US FDA granted RMAT designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease.